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Abstract 
Completion of the human genome sequencing project highlighted the richness of the cellular RNA world, and 
opened the door to the discovery of a plethora of short and long non-coding RNAs (the dark transcriptome) with 
regulatory or structural potential, which shifted the balance of pathological gene alterations from coding to non-cod-
ing RNAs. Thus, disease risk assessment currently has to also evaluate the expression of new RNAs such as small micro 
RNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), competing endogenous RNAs (ceRNAs), 
retrogressed elements, 3′UTRs of mRNAs, etc. We are interested in the pathogenic mechanisms of atherosclerosis 
(ATH) progression in patients suffering Chronic Kidney Disease, and in this review, we will focus in the role of the 
dark transcriptome (non-coding RNAs) in ATH progression. We will focus in miRNAs and in the formation of regula-
tory axes or networks with their mRNA targets and with the lncRNAs that function as miRNA sponges or competitive 
inhibitors of miRNA activity. In this sense, we will pay special attention to retrogressed genomic elements, such as pro-
cessed pseudogenes and Alu repeated elements, that have been recently seen to also function as miRNA sponges, as 
well as to the use or miRNA derivatives in gene silencing, anti-ATH therapies. Along the review, we will discuss techni-
cal developments associated to research in lncRNAs, from sequencing technologies to databases, repositories and 
algorithms to predict miRNA targets, as well as new approaches to miRNA function, such as integrative or enrichment 
analysis and their potential to unveil RNA regulatory networks.
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Background. Atherosclerosis progression 
and the dark transcriptome
Atherosclerosis (ATH) is a complex inflammatory dis-
ease of the vessel wall caused by a combination of multi-
ple factors including genomics, epigenetic modifications 
and environmental conditions, that place an enormous 
burden on modern societies, particularly in the aging 
population [1]. The complexity of its causes and mecha-
nisms makes ATH prevention and treatment largely inef-
fective, becoming an enormous challenge for our society, 
favored by our lifestyle [2, 3]. Thus, there is an urgent 
need to develop a more personalized medicine, and to 
enhance patient care through improved diagnostic sensi-
tivity with more effective interventions in ATH preven-
tion and treatment [4]. In this sense, years of research 
on the genomic basis of ATH have provided the bio-
medical community with a knowledge of gene-related 
ATH risk factors, such as SNPs [5, 6], genes and gene 
variants [7–9], alterations in DNA methylation [10, 11], 
changes in gene expression [12, 13], etc. Nevertheless, in 
the last years a new player has entered the game of dis-
ease-associated genes: the highly heterogeneous group 
of non-coding RNAs, which are progressively becoming 
important factors for atherosclerosis (and other diseases) 
research either as biomarkers of disease progression or 
as pathophysiological intermediates, while their opera-
tive interactions highlight the remarkable structural and 
functional complexity of the human genome.
Open Access
*Correspondence:  estanis.navarro@gmail.com; mhueso@idibell.cat
2 Department of Nephrology, Hospital Universitari Bellvitge and Bellvitge 
Research Institute (IDIBELL), C/Feixa Llarga, s/n; L’Hospitalet de Llobregat, 
08907 Barcelona, Spain
Full list of author information is available at the end of the article
Page 2 of 18Navarro et al. Clin Trans Med             (2020) 9:5 
From junk to gold, non‑coding RNAs are functional 
components of the human transcriptome
Analysis of the sequenced human genome showed that 
over 80% of the genome could be considered as bio-
chemically active [14], most of it in the form of DNase 
I-accessible loci or candidate regulatory sequences [15–
17]. Although the number of protein coding genes in the 
human genome has been recently estimated at 20–25,000 
[18, 19], the total number of active genomic loci is signifi-
cantly higher, with a best guess being close to 10e5 [20] 
most of them corresponding to a plethora of heterogene-
ous, non-protein-coding, RNAs [21]. Originally consid-
ered as part of the “dark transcriptome” or “genomic dark 
matter”, i.e. genomic sequences of uncertain or unknown 
function [22, 23], non-coding RNAs were initially classi-
fied by their length into short (< 200 nucleotides long) and 
long (lncRNAs, > 200 nucleotides long) RNAs. Although 
some efforts have been devised to make a more informa-
tive and standardized nomenclature of ncRNAs [24, 25], 
this primary classification based in length is still widely 
accepted by the scientific community, and we will fol-
low this convention in this review. Short ncRNAs include 
the already known snRNAs, snoRNAs and tRNAs, the 
PIWI-associated RNAs that repress expression of trans-
posable and repetitive elements in the germline to main-
tain genomic stability [26] and the microRNA (miRNA) 
family of translational regulators (see the  “MicroRNAS 
(miRNAs), a family of pleiotropic translational regula-
tors”  section here and [27] for a review). On the other 
hand, lncRNAs conformed a highly heterogeneous group 
in size and function, with regulatory roles in develop-
ment, differentiation and disease progression [28–31], 
and whose expression is frequently altered in disease (see 
“Long non-coding RNAs (lncRNAs) and their functional 
relationship with miRNAs” section here  and [32] for a 
review).
Data on the expression of non-coding RNAs have 
drawn a new model of the human genome function in 
which the nucleus is pervasively transcribed, even in 
intronic and intergenic sites [33], to generate a com-
plex population of short and long non-coding RNAs 
with putative regulatory functions [34]. Although this 
model has been challenged on technical bases [35, 36], it 
is now widely accepted that in the mammalian genome 
over one order of magnitude more genomic sequence is 
transcribed to non-coding RNA than to protein-coding 
RNA [37]. This new model has also changed the origi-
nal paradigm on the flow of genetic information from 
the linear “DNA makes RNA makes protein”, for many 
years considered as the central dogma of molecular biol-
ogy [38, 39], to a multilayered process characterized by 
the pervasive expression of many structural or regula-
tory RNAs with the ability to establish different tiers of 
functional interactions (Fig. 1). This change of paradigm 
has had a number of consequences, such as the exponen-
tial increase in the number of non-protein coding RNAs 
associated to diseases, drawing new layers of epigenetic 
control that confer regulatory plasticity and are deregu-
lated in disease, and the need to profile and give sense to 
these expression alterations and to the huge amount of 
expression data generated by disease-associated sequenc-
ing projects.
Our group is interested in the role of ncRNAs in the 
context of ATH progression. Here, we will review recent 
developments on the impact of non-coding RNAs on 
ATH progression, focusing on the role of microRNAs. 
We will also study their functional relationship with 
lncRNAs, since these have been reported to play key 
functions in physiology and disease [40], and to have a 
role in miRNA function as miRNA “sponges” or competi-
tive inhibitors of miRNA activity. Furthermore, in this 
group of lncRNAs we will also include other transcripts, 
such as pseudogenes, and expressed Alu elements, which 
have been reported to also interact with miRNAs but that 
have been less studied.
DNA sequencing and the integration 
of transcriptomics with personalized medicine
In less than 25  years, DNA sequencing [41, 42] evolved 
from a technique only available to the elite of basic 
research laboratories to a tool widely used in clinical 
settings, a technical evolution that crystallized in the 
sequencing of the human genome by two scientific con-
sortia [43, 44] and opened the age of the personalized 
















Fig. 1 The “central dogma” revisited. Shown are new additions to 
the central dogma (boxed), highlighting the fundamental role of 
miRNAs in the regulation of gene expression. This work reviews the 
functional relationships among the RNAs drawn in red. Black arrows 
means transcription or translation, double-headed red arrows mean 
mutual interactions, red arrows functional interactions (in the case of 
pseudogenes and Alu elements, retroinsertion) and dotted lines refer 
to the histone code and chromatin modifications
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whole genomes or exomes is performed in all branches of 
medicine as a prognostic or diagnostic tool, or to follow 
treatment or disease progression. Furthermore, single-
cell RNA-sequencing (scRNA-seq) methodologies allow 
the genome-wide profiling of individual cells to identify 
mutations and to characterize and quantify cellular het-
erogeneity and its variations in disease [45].
Open sequence repositories, the key to the sequencing 
revolution
One key factor of success of the sequencing revolu-
tion has been the almost immediate accessibility to all 
sequences generated in research laboratories, many times 
even prior to publication. This was possible because of 
the establishment of three mirrored sequence reposito-
ries (GenBank at the NCBI, DNA DataBank of Japan and 
the European Nucleotide Archive, Table  1) that stored, 
annotated and provided public and unrestricted access to 
all DNA and RNA sequences in the context of the Inter-
national Nucleotide Sequence Database Collaboration 
[46]. One critical point of these repositories is that these 
not only facilitated the diffusion of DNA/RNA sequences 
by giving each one of them a unique sequence identi-
fier, but also created a database of “reference genomes”, 
a collection of non-redundant, reference genomic, 
transcriptomic and protein sequences, intended to func-
tion as primary sequence references in genomic works 
[47, 48]. Furthermore, these also provided diverse anno-
tations to the sequences, from functional domains to 
genomic loci, intended as maps of the genomic landscape 
to facilitate the interpretation of the genomic context of a 
specific sequence [20]. Lastly, all these information have 
been integrated in “genomic browsers” (Ensembl [49], 
and NCBI’s genome viewer [50]) which allow users going 
from chromosome regions to the sequence of any tran-
scriptional unit and its variants.
The revolution in sequencing technologies
Initial sequencing protocols used ultrathin PAGE gels 
to resolve radioactively-labelled fragments [51, 52]. 
Although DNA sequencing was subsequently improved 
by the introduction of fluorescent labels [53] and by the 
use of the thermostable Taq DNA polymerase [54, 55], 
these methods were not adaptable to the high through-
put-approach requisites of clinical sequencing. In this 
context, sequencing of the human genome started a 
race for new methods and faster and cheaper sequenc-
ing machines, with the objective set at the “1000 $ 
genome” [56], that prompted different approaches to 
the high-throughput sequencing of DNA. Aside of the 
pore sequencing (Oxford Nanopore) that perform a 
direct sequencing by using protein nanopores without 
DNA synthesis or amplification [57], most of the current 
sequencing platforms use a highly/mass parallel approach 
[58]. In this approach, the original sample (genomic 
DNA for genome sequencing or RNA copied as cDNA 
for exome sequencing) is fragmented and the fragments 
immobilized in individual cells where they are amplified, 
cycle-copied with labeled nucleotides and each reaction 
is individually detected as fluorescence (Illumina, Qiagen 
Gene reader or Pacbio platforms), or as  H+ (Ion torrent 
platform). Lastly, each sequence is compared with refer-
ence genomes or exomes for identification [58].
The technical challenge of sequencing ncRNAs
Sequencing ncRNAs suppose a technical challenge 
derived of their heterogeneous length and exonic compo-
sition since these have sizes ranging from the 22 nucleo-
tides of mature miRNAs [59] to the 22.7 kb of the single 
exon NEAT1_v2 transcript [60]. One possibility to over-
come this problem is performing short sequence reads, 
like the expressed sequence tags (ESTs) in which indi-
vidual cDNA clones were sequenced by their 3′ end only, 
generating reads of a few hundred nucleotides that were 
as “tags” of the full-length transcript [61]. Although this 
approach is suitable for the construction of genetic and 
physical maps of expressed sequences [62–64], it would 
not detect all the richness of CDS mutations (required 
Table 1 Sequence databases and repositories
Shown are repositories, databases data viewers of nucleic acids. This is not an 





DDBJ, DNA Databank of 
Japan
-www.ddbj.nig.ac.jp
ENA, European Nucleotide 
Archive
-www.ebi.ac.uk/ena
INSDC (and Sequence 
Read Archives)
-insdc .org
NCBI Reference Sequence 
Database (Refseq)
-www.ncbi.nlm.nih.gov/refse q/
Ensembl Genome Viewer -www.ensem bl.org
Genome Data Viewer -www.ncbi.nlm.nih.gov/genom e/gdv/
miRBase -www.mirba se.org
LNCipedia Project (data-





RNA central (ncRNA 
sequence database)
-rnace ntral .org




tation of the human 
genome
-fanto m.gsc.riken .jp
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for cancer research) or the complex patterns of alterna-
tive splicing that display lncRNAs. In this sense, and as 
an example, the relatively “short” 3.8  kb ANRIL [65], is 
expressed as over 50 splicing isoforms, linear or circu-
lar [66, 67], some of them disease-related [68]. In this 
complex context it is evident that recovering most of the 
lncRNA genomic information will require not only devel-
oping new sequencing hardware able to provide longer 
and more accurate reads, but also to improve the ability 
of reverse transcriptase (RT) to copy as much as possi-
ble of the full-length sequence, although these problems 
could be circumvented by a more “classical” molecular 
biology approach using random primers for the RT reac-
tion, followed by the painstaking growth of the sequence 
by the 5′/3′ RACE (rapid amplification of cDNA ends) 
technique [69].
On the other hand, and for the case of small miRNAs, 
the entire population of a tissue can be sequenced by gel-
purifying the fraction of small RNAs, adding them 5′ and 
3′ adaptors with T4 RNA ligase, followed by a reverse 
transcription and PCR amplification prior to sequencing 
in any of the above platforms. In this way, representa-
tive results are obtained even for low expressed miRNAs, 
since the number of reads is proportional to the number 
of initial miRNA copies [70]. Furthermore, when deal-
ing with miRNAs, the new high-throughput sequencing 
techniques have the potential to provide single-nucle-
otide resolution of miRNA species, facilitate de novo 
miRNA discovery and offer a dynamic range for miRNA 
quantification [71].
MicroRNAS (miRNAs), a family of pleiotropic 
translational regulators
MiRNAs are small RNAs (over 22 nucleotides long) with 
important roles in post-transcriptional gene regulation 
[59]. MiRNA genes are under transcriptional control, are 
transcribed by RNA polymerase II and suffer a process of 
maturation from pri-miRNA primary transcripts to the 
fully functional mature miRNAs which include activity of 
RNase III endoribonucleases DROSHA and DICER (see 
[72, 73] for reviews). In a recent work, Alles et al. estimated 
the entire human miRNAome as being composed by 2300 
mature miRNAs of which 1115 were annotated in the ver-
sion 22 of the specific miRNA database, miRbase [74]. 
MiRNAs function by targeting mRNAs, usually by base-
pairing at their 3′UTR, for degradation or translational 
repression through the RISC complex (RNA Induced 
Silencing Complex) [27]. Recent reports estimated that 
over 60% of mRNAs harbour miRNA binding sites at their 
3′UTRs, highlighting the importance of this interaction for 
the fine-tuning regulation of translation [75, 76]. An inter-
esting characteristic of miRNA function is their functional 
promiscuity. Since only 6 bases of miRNA/mRNA com-
plementarity are enough for duplex formation [77], a sin-
gle miRNA can target dozens of different mRNAs which 
in turn can be regulated by many different miRNAs, thus 
creating a complex regulatory network [78].
Dynamics of 3′UTRs: more than a counterpart for miRNA 
function
3′UTR regions of mRNAs are highly polymorphic 
in length and sequence, variations that may under-
lie changes in miRNA targeting and stability of the 
involved mRNAs [79]. Length polymorphisms of 
3′UTRs are due to two different mechanisms: alter-
native splicing of untranslated exons, which is shared 
with most RNAs, and alternative polyadenylation, 
which seems to be mostly restricted to mRNAs, lin-
cRNAs and NATs [80]. In a seminal work, Liaw et  al. 
showed that cancer cells expressed shorter 3′UTRs 
than normal cells [81], suggesting that 3′UTR length-
ening could constitute a mechanism to control accessi-
bility to miRNA sites whose de-regulation could result 
in disease [82, 83], and suggesting that the 3′UTRome 
should be studied not only as a catalogue of miRNA 
binding sites but as a dynamic structure whose de-
regulated changes could lead to the identification of 
new risk factors, or new candidates for disease genes 
[83]. Nevertheless, the effects of 3′UTR heterogeneity 
on the patterns of miRNA binding is a poorly studied 
topic, despite its potential importance, and there are 
only a few reports published. Without the aim of being 
exhaustive, since this topic will be treated more in 
deep in another work (Navarro et al. in progress), there 
are published examples on the regulation of miRNA 
activity by alternative 3′UTRs. In this sense, Xiao 
et  al., showed that alternative polyadenylation at the 
3′UTR of AAMDC originated two isoforms that dif-
fered in length and that only the long isoform was sus-
ceptible to miR-2428/664a silencing [84], while Bruhn 
et al. identified five different 3′-UTR length variants in 
the ABCB1 gene, of which only the three longer frag-
ments harbored miRNA binding sites [85], and Pereira 
et  al. working on the transcription factor Nurr1 
(NR4A2), from the superfamily of nuclear receptors 
identified a number of 3′UTR length variants in the 
rat Nurr1 mRNA and described the selective interac-
tion of miR-93, miR-204 and miR-302d with the long-
est Nurr1 mRNA [86]. Lastly, we have recently shown 
that a splicing event at an internal/cryptic splice site of 
the murine Cd34 gene would regulate the differential 
accession of miRNA-125/351 to the 3′UTR or the CDS 
of the Cd34mRNA [87] (Fig. 2).
Page 5 of 18Navarro et al. Clin Trans Med             (2020) 9:5 
MicroRNAs in ATH progression
There is already a corpus of literature on the genet-
ics and epigenetics of ATH evolution (see [40, 88, 89] 
for recent reviews), so that here in this section and in 
the next sections we will review recent developments 
on the relationship among miRNAs and ATH onset 
and progression and will highlight their use as thera-
peutic tools. In this sense, there are sound evidences 
demonstrating the involvement of miRNAs in many 
of the pathological processes that occur in ATH, and 
hundreds of miRNAs have been reported as key regu-
lators of lipid handling, inflammation and cellular 
behaviors such as proliferation, migration and pheno-
typic switch [90], with alterations in the expression of 
miRNAs being detected not only in primary tissues 
but also in serum [91], urine [92], and exosomes [93]. 
Many reports have been published assessing modula-
tion of miRNA expression in human patients and in 
mice models of ATH, some of them described in rela-
tively mechanistic depth [94]. Table  2 reports recent 
descriptions of ATH-associated miRNAs either in ani-
mal models or in samples from human patients, their 
mRNA targets validated by luciferase reporter assays 































Fig. 2 Impact of alternatively expressed 3′UTRs on their interaction with miRNAs. Shown are changes in the structure of the 3′UTRs with the 
potential to impact on the binding of specific miRNAs. 1. The existence of alternative polyadenylation signals originate 3′UTRs of different lengths 
and different potential for miRNA binding. 2. Alternative exons encoding different 3′UTRs differ in their potential for miRNA binding. 3. Exonic 
switch. In the case of the Cd34 gene, an internal cryptic splice site (CSS) activates two different stop codons and generates two different exons 8, 
with the consequence that in one Cd34 isoform the binding site for a number of miRNAs is located in the 3′UTR, while in the other isoform it is 
located inside the CDS (taken from [87])
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their expression alterations on ATH progression. This 
highlights the complexity of the miRNA/mRNA system, 
with different miRNAs targeting the same mRNA (e.g. 
miR-103 and miR-647 vs. PTEN), and a single miRNA 
targeting different mRNAs with different phenotypic 
outputs (miR-370 vs. FOXO1 and TLR4).
Small RNAs in gene‑silencing therapies
Recent years have seen a trend to develop gene-silencing, 
small-RNA-based, therapies to specifically target mRNAs 
or other miRNAs [115, 116], an approach well-suited to 
target undruggable targets or polygenic pathologies given 
the ability of small-RNAs to target multiple mRNAs and 
pathways [117]. The list of miRNA-based, gene silenc-
ing (or mimicking) tools is growing and includes agomirs 
or single-stranded miRNAs (ss-miRNAs) and antago-
mirs (oligonucleotides containing the complementary 
sequences of the target miRNA), double-stranded small-
interference RNAs (ds-siRNAs), or miRNA sponges 
([118] and see next section). With a growing number 
of possible siRNA targets in ATH research [119], sev-
eral  other RNA-therapies are currently in clinical trials 
[120]. Thus, the first siRNA-based drug (Patisiran) has 
recently obtained the FDA approval to silence the tran-
sthyretin (TTR) mRNA (via RNA-interference by binding 
its 3′UTR) which caused a rare transthyretin-mediated 
amyloidosis polyneuropathy originated by the deposit of 
TTR-protein in tissues [121]. Other miRNA-candidates 
for medical intervention are currently in clinical devel-
opment or in phase 1 or phase 2 clinical trials, such as 
Table 2 ATH-associated miRNAs, mRNA targets and the effects of their expression on ATH progression
U/R Up-regulation, D/R downregulation
Abbreviations of the cells and cell lines used in the works referenced: HA-VSMCs human aorta vascular smooth muscle cells, ASMCs human aortic smooth muscle 
cells, HCASMCs human coronary artery smooth muscle cells, HUVECs human umbilical vein endothelial cells, HAECs human aortic endothelial cells, HMEC-1 human 
microvascular endothelial cell line, ERS endoplasmic reticulum stress
a All the target mRNAs have been validated by luciferase reporter assays
miRNA Target mRNA/sa Effect of miRNAs on ATH progression References
miR-9 Oxidized low-density lipoprotein (lectin-like) receptor 1 
(OLR1)
ApoE-null mice (U/R protective) [95]
miR-23a-5p ATP-binding cassette transporter A1/G1 ABCA1/G1 U/R promotes macrophage-derived foam cell formation [96]
miR-23b Forkhead Box O4 (FoxO4) U/R inhibited VSMC proliferation and migration [97]
miR-25-3p A disintegrin and metalloprotease 10 (Adam10) ApoE-null mice (U/R protective) [98]
miR-30-3p Transcription factor 21 (TCF21) U/R increases viability of HUVEC cells [99]
miR-34a BCL2 apoptosis regulator (BCL2) D/R facilitated growth and blocked apoptosis in HAECs [100]
miR-98 Receptor for ox-LDL 1 (LOX-1) D/R inhibited foam cell formation and lipid accumulation in 
aortas of ApoE-null mice
[101]
miR-99a-5p Homeobox A1 (HOXA1) U/R inhibits proliferation and invasion of ASMCs [102]
miR-103 Phosphatase and tensin homolog (PTEN) D/R suppressed inflammation and ERS in ECs from ApoE-
null mice
[103]
miR-124 MCL-1 apoptosis regulator (MCL-1) U/R represses viability, migration and capillary structure 
formation in HMEC-1 cells. Sponged by lncRNA HULC
[104]
miR-135b Erythropoietin receptor (EPOR) C57BL/6J male mice (D/R protective) [105]
miR-142-3p Rapamycin-insensitive companion of MTOR (Rictor) D/R inhibited ECs apoptosis and ATH development in 
HAECs
[106]
miR-223 Insulin growth factor-1 receptor (IGF-1R) U/R inhibits foam cell formation in VSMCs of human ATH 
patients
[107]
miR-338-3p BMP and activin membrane-bound inhibitor (BAMBI) D/R promoted viability and inhibited apoptosis in ox-LDL-
induced HUVECs
[108]
miR-365b-3p A disintegrin and metalloproteinase with thrombospondin 
motifs 1 (ADAMTS1)
U/R attenuated PDGF-BB-induced proliferation and migra-
tion of HCASMCs
[109]
miR-370 Forkhead Box 1 (FOXO1) U/R promotes invasion and proliferation of HUVECs [110]
miR-370 Toll-like receptor 4 (TLR4) U/R inhibits IL-6 and IL-1β expression and ROS levels in 
THP-1 cells
[111]
miR-451 14-3-3 ζ (YWHAZ) U/R improves intimal thickening in rats following vascular 
injury
[112]
miR-590 Toll-like receptor 4 (TLR4) U/R inhibited atherosclerotic lesion in ApoE-null mice and 
HAECS
[113]
miR-647 Phosphatase and tensin homolog (PTEN) Upregulated in HA-VSMCs [114]
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MRG-110, a locked nucleic acid (LNA)-modified anti-
sense oligonucleotide against miR-92 with a potential 
clinical application in wound healing and heart failure 
[122], a miR-29b mimic (Remlarsen) to prevent forma-
tion of fibrotic scars or cutaneous fibrosis [123], or anti-
miR-21 oligonucleotides, which were seen to alleviate 
kidney disease in a murine model of Alport nephropathy 
[124]. On the other hand, miRNA-mimics or antagomirs 
have been also used at the laboratory level to modulate 
miRNA expression in ATH research [125], and recently 
therapies directed against miR-449a [126], miR-23a-5p 
[109], or miRNA-98 [112], among others, have been 
tried in animal models with encouraging results. Lastly, 
therapeutic miRNAs are not restricted to targeting spe-
cific mRNAs or miRNAs, and have been also used as co-
factors to limit drug resistance through silencing of key 
proteins promoting low drug bioavailability [127].
Nevertheless, the use of miRNAs in gene-silencing (or 
gene-mimicking) therapies has yet to overcome a num-
ber of difficult issues such as developing efficient deliv-
ery vehicles, reducing unwanted off-target, side effects, 
or blocking immune activation. Without the aim of 
being exhaustive (see [128–130] for recent reviews on 
the topic), here we will cite some of the main drawbacks 
associated to the design of miRNA/siRNA delivering 
vehicles, such as the limitation in the amount of loaded 
siRNA due to the rigidity of ds-siRNAs and the low sur-
face charge of individual siRNAs that make encapsulation 
challenging [131]. Furthermore, conventional complexa-
tion or encapsulation with lipids nanoparticles, cationic 
complexes, inorganic nanoparticles, RNA nanoparticles 
and dendrimers introduce a significant amount of vehi-
cle which can lead to greater potential for immunogenic 
response or toxicity [132]. A plausible alternative is the 
systemic delivery with injections or intravenous admin-
istration, since injections of miRNA drug directly into 
the pathogenic site have been seen to enhance target 
specificity, efficacy and to minimize side effects [133]. In 
this sense, a number of chemical modifications, e.g. with 
phosphorothioate, 2′-O-methyl-phosphorothioate, N,N′-
diethyl-4-(4-nitronaphthalen-1-ylazo)-phenylamine or 
the LNA-nilation (locked nucleic acid) have been seen to 
increase stability of the DNA/RNA moiety [134]. Lastly, 
new strategies are being pursuit to facilitate specific 
delivery of the miRNA/siRNA cargo, such as the addi-
tion of targeting moieties (specific antibodies) against 
a protein from target cells linked to the delivery vehicle 
to enhance its therapeutic efficacy [135], or the “Tar-
gomiRs”, mimicking miRNAs delivered by targeted bacte-
rial minicells [136].
On the other hand, miRNA/siRNA therapies also 
have the potential for silencing off-target genes, causing 
unexpected adverse effects due to partial sequence com-
plementarity to 3′UTRs, this meaning a significant obsta-
cle to the therapeutic application of miRNAs [137]. In 
this sense, we have recently reported that systemic treat-
ment with an anti-CD40-siRNA increased renal NF-kB 
activation in the ApoE-deficient mice model of ATH 
(Hueso et  al., J. Inflammation, in the press). Further-
more, a phase 1 trial with an anti-tumour miRNA-34 
mimic (MRX34) was stopped in 2016 after severe adverse 
events were reported in five patients who experienced 
a serious immune response [116], and another phase 1 
trial on patients with malignant pleural mesothelioma, 
treated with a TargomiRs loaded with miR-16 and tar-
geted to EGFR, reported infusion-related inflammatory 
symptoms and cardiac events [138], indicating the need 
for more research on the impact of carriers, vehicles and 
therapeutic nucleic acids on the inflammatory response.
Long non-coding RNAs (lncRNAs) and their 
functional relationship with miRNAs
LncRNAs and miRNA sponges
Long non-coding RNAs (lncRNAs) represent a heteroge-
neous class of non-coding RNAs that includes transcripts 
> 200 nucleotides, which lack functional protein cod-
ing ability but modulate gene expression through mul-
tiple distinct mechanisms at epigenetic, transcriptional 
or post-transcriptional levels [139]. LncRNAs coordi-
nate and integrate multiple signaling pathways and have 
important roles in development, differentiation, and dis-
ease [140–143]. Currently estimated at more than 56,000 
[144], the number of lncRNA genes more than dou-
bles the number of protein-coding genes in the human 
genome, although due their low expression levels, many 
lncRNAs remain poorly characterized and annotated 
[145], so that it is likely that this number will be increased 
in the years to come. Based on their presumed function 
lncRNAs have been classified in a number of functional 
groups: competitive endogenous lncRNAs (ceRNAs) 
and circular lncRNAs (circRNAs), with potential roles 
as miRNA inhibitors [146, 147], enhancer-related RNAs 
(eRNAs), involved in transcriptional regulation [148], 
transcribed ultraconserved RNAs (T-UCRs), transcribed 
from non-coding highly conserved genomic regions 
[149], and the highly heterogeneous natural antisense 
transcripts (NATs), intronic lncRNAS and long intergenic 
RNAs (lincRNAs) among others, although this classifica-
tion is neither exhaustive (see [150] for a recent and com-
prehensive review on the topic) nor unambiguous since a 
lncRNA could easily fit into more than one group [151].
We are especially interested in the lncRNAs that inter-
act with miRNAs and function as competitive inhibitors 
of miRNA action (“sponges”), creating loss-of-function 
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miRNA phenotypes and causing the de-repression of its 
targets [152, 153]. In the next sections we will give an 
overview of the role of these transcripts in the regulation 
of miRNA function, and when data are available in ATH 
progression.
LncRNAs in ATH progression and therapy: the case 
for ANRIL
High-throughput sequencing has allowed an exponen-
tial growth in the amount of sequence data generated in 
large number of individuals, and expanded the number of 
non-coding RNA (ncRNA) transcripts predicted to play 
a critical role in the pathogenesis of ATH [4] (Table  3), 
although because of their low expression levels, the 
study of lncRNAs is actually so challenging that many of 
them still remain poorly characterized and annotated. 
The lncRNA more clearly associated to ATH pathogen-
esis is CDKN2B-AS1, also known as ANRIL (Antisense 
Non-coding RNA in the INK4 locus) (see [1] for a recent 
review), that it is transcribed from chromosome 9p21 
and acts as a lncRNA-guide to localize the polycomb 
repressive complex (PRC) at target promotors through a 
direct interaction with its subunits CBX7 or SUZ12 [154]. 
ANRIL is induced by the activation of the NF-kB path-
way, and up-regulated ANRIL forms a functional com-
plex with transcriptional factor Yin Yang 1 (YY1) to exert 
transcriptional regulation on inflammatory genes IL6 
and IL8 in endothelial cells, while knockdown of ANRIL 
was seen to inhibit TNFα-induced expression of IL6 and 
IL8 expression [155], thus highlighting the involvement 
of ANRIL in the TNFα/NF-kB signalling that regulate 
inflammatory response. ANRIL expression was seen to 
be also correlated with a proliferative phenotype in vas-
cular smooth muscle cells (VSMC) [156] and to act in 
trans, via Alu repetitive elements, to regulate other genes 
that participate in proatherogenic pathways [157]. Lastly, 
it has been reported a role for ANRIL as miRNA sponge 
in different tumours, such as miR-199a in triple-negative 
breast cancer [158], miR-186 in cervical cancer [159], or 
miR-323 in pediatric medulloblastoma [160].
Competitive endogenous lncRNAs (ceRNAs) and circular 
lncRNAs (circRNAs)
Competing endogenous RNAs (ceRNAs) and circular 
lncRNAs (circRNAs) could be described as the “profes-
sional” miRNA “inhibitors/sponges”, i.e. the families of 
lncRNAs that work as “dominant negatives” of miRNA 
action by interacting with their seed regions to poten-
tially block whole families of related miRNAs [152, 177]. 
This interaction cause the de-repression of their down-
stream targets, because miRNA-target interaction is 
strongly concentration-dependent [178], and has been 
seen to be de-regulated in a number of pathological 
conditions, from cancer to neurodegenerative diseases 
[179, 180]. CircRNAs are generated, by the thousands, 
from exonic or intronic regions in mammalian cells by 
a back-splicing event that links covalently the 3′ and 5′ 
ends of the transcript, so that they do not have a 5′ cap 
Table 3 lncRNA:miRNA:mRNA axis in atherosclerosis progression
For each lncRNA shown are also a sponged miRNA and one mRNA target of this last, as well as the effect of the RNA network on ATH progression. n.d. not determined
Abbreviations of the tissues, cells and cell lines used in the works referenced: CAVD calcified aortic valve disease, HA-VSMCs human aorta vascular smooth muscle cells, 
HUVECs human umbilical vein endothelial cells, HAECs human aortic endothelial cells, HMEC-1 human microvascular endothelial cell line, VICs human valve interstitial 
cells, VECs vascular endothelial cells
lncRNA Sponged miRNA Target mRNA Regulated pathway in ATH progression References
MALAT1 miR-204 SMAD4 Osteogenic differentiation in CAVD [161]
MALAT1 miR-320a FOXM1 Proliferation of HUVECs [162]
MIAT miR-181b STAT3 Proliferation and apoptosis in HA-VSMC cells [163]
MIAT miR-149-5p CD47 Promoted atherosclerosis progression [164]
MEG3 miR-26a SMAD1 Proliferation of vascular smooth muscle cells [165]
MEG3 miR-223 NLRP3 Pyroptosis in HAEC cells [166]
DIGIT miR-134 Bmi-1 Viability, migration and apoptosis of HMEC-1 cells [167]
GSA5 miR-221 MMPs Inflammatory response in THP-1 cells [168]
Linc00657 miR-590-3p HIF-1α Angiogenesis [169]
TUG1 miR-204-5p Runx2 Osteoblast differentiation in human aortic VICs [170]
Linc00299 miR-490-3p AURKA Proliferation of vascular smooth muscle cells and HUVECs [171]
UCA1 miR-26a PTEN Proliferation of vascular smooth muscle cells [172]
Linc00305 miR-136 n.d. Proliferation and apoptosis of HUVECs [173]
MKI67IP-3 Let-7e IκBβ Inflammatory response in VECs [174]
H19 miR-148b WNT1 Proliferation and apoptosis of HA-VSMCs [175]
RNCR3 miR-185-5p KLF2 Proliferation of ECs and VSMCs [176]
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or 3′ tail [181, 182], and their expression is submitted to 
tissue/developmental-stage-regulation [183]. In recent 
years a number of groups have reported on the impact 
of lncRNA-sponges on ATH and related cardiovascu-
lar conditions with a mechanistic detail that include co-
regulated miRNA and mRNA targets [184–186], and this 
is becoming a hot topic in cardiovascular research (see 
Table 3).
Transcribed ultraconserved RNAs (T‑UCRs)
The first T-UCR RNA to be described was Evf-2, tran-
scribed from the ultraconserved region between the 
homedomain containing genes Dlx-5 and Dlx-6. At the 
functional level, Efv-2 works as a coactivator of Dlx-2 
to increase the activity of the transcriptional enhancer 
close to the Dlx-5/6 cluster [187]. Expression of T-URCs 
is tightly regulated, and a number of them (Uc.160+, 
Uc283+A and Uc.346+, Uc for Ultra Conserved) were 
seen to be silenced through DNA methylation at spe-
cific CpG islands in transformed cells [188]. Other dis-
ease associated T-UCRs have been detected, mainly in 
tumours, thus Uc.416+A was seen to be upregulated in 
renal cell carcinoma [189], as Uc.383 in hepatocellular 
carcinoma [190], Uc.338 in colorectal cancer [191], or 
Uc.63 in breast cancer ([192], see also [149] for a recent 
review). Interestingly, a number of authors have reported 
regulatory interactions among T-UCRs and miRNAs. In 
this sense, it was seminal the report of a direct interac-
tion of Uc.283+A with pri-miR-195 that prevented the 
cleavage of this last by Drosha and hindered its matura-
tion [193]. Subsequently, other authors have described 
further T-UCR/miRNA interactions such as that of 
Uc.173 with miRNA-195 [194] or miR-29b [195] to facili-
tate function of the intestinal epithelium, or the interac-
tion of Uc.416+A with miR-153 in renal cell carcinoma 
[189].
Natural antisense transcripts (NATs)
NATs is a highly heterogeneous group of lncRNAs, tran-
scribed from the complementary chain of target genes 
in an antisense orientation, that regulate post-tran-
scriptionally gene expression via RNA:RNA interactions 
with mRNA or miRNAs [196]. In this sense, oncogenic 
lncRNA FOXD1-AS1 (FOXD1-antisense 1), the antisense 
transcript of the gene FOXD1, was reported to interact 
with miR339-5p and miR342-3p [197], tumor suppressor 
TP73-AS1 sponged miR-941 [198], while TSPAN31, the 
natural antisense transcript of cyclin dependent kinase 4 
(CDK4), interacted with miR-135b in hepatocellular car-
cinoma  causing TSPAN31 silencing and the subsequent 
upregulation of CDK4 [199].
Retrogressed genomic elements: processed pseudogenes 
and Alu repeated elements
Retrogressed genomic elements conform an heteroge-
neous group of expressed mRNAs that have made their 
way back into the genome through retrogression, i.e. a 
cycle of retrotranscription (mRNA to cDNA), and inser-
tion (cDNA into genomic DNA) catalysed by the reverse 
transcriptase and endonuclease activities of the LINE 
retrotransposons [200]. Among them the best character-
ized are the processed pseudogenes, originated by the 
retrogression of a functional mRNA, and the repeated 
sequences of the Alu family, a member of the Short Inter-
spersed Nuclear Elements (SINEs) group that come from 
a founder Alu element.
Processed pseudogenes underwent 3′-end polyadenyla-
tion and do not contain introns, since they come from 
fully-spliced transcripts, are flanked by duplicated inte-
gration sites 5 to 20 bp in length and upon genomic inte-
gration they suffer a process of sequence degeneration 
[201]. Pseudogenes were initially considered as the par-
adigm for “junk DNA” since these were genes (mRNAs) 
that lost its coding function, but recent works have re-
evaluated their function and now it is widely accepted 
that they have a role in the regulation of gene expression 
and that its dysregulation is often associated with various 
human diseases including cancer [202]. According to last 
estimates, the number of processed pseudogenes in the 
human genome is similar to that of “true” coding genes 
[201], and some of them have been seen to function as 
miRNA sponges [203]. Although expressed pseudogenes 
could be considered as the perfect miRNA sponges since 
they provide mostly homologous miRNA binding sites in 
the correct sequence context, leading to the paradox that 
expression of the pseudogene could regulate expression 
of its corresponding gene [204], there are several con-
straints that could impact on the role of pseudogenes in 
miRNA function. Thus, the sequence degeneration sub-
sequent to the integration of pseudogenes in the genome 
might inactivate miRNA binding sites, while the genomic 
context of the integration site could impose patterns of 
expression different from those of the parental gene. 
Nevertheless, the most critical factor is the difference in 
gene-number among the parental gene and its pseudo-
gene progeny since not all genes have their correspond-
ing expressed pseudogenes while a number of them are 
overrepresented in the pseudogene count, as the 2090 
pseudogenes found for the 79 genes encoding human 
ribosomal proteins, from which 145 pseudogenes corre-
spond to the RPL21 [205]. Despite these constraints, sev-
eral groups have characterized different pseudogenes as 
miRNA sponges, and a manually curated database (miR-
sponge) has been created [203]. Thus PMS1 Homolog 
2, Mismatch Repair System Component Pseudogene 2 
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(PMS2L2) has been described as a molecular sponge of 
miR-203 in osteoarthritis, with MCL-1 mRNA being 
the direct target of miR-203 [206], ferritin heavy chain 
1 pseudogene 3 (FTH1P3) was shown to suppress miR-
206 activity to promote ABCB1 (ATP binding cassette 
subfamily B member 1) protein expression [207], and to 
sponge miR-224-5p to modulate expression of fizzled 5 
[208]. Furthermore, OCT4-pseudogene 4 was shown to 
protect OCT4 mRNA from miR-145 [209], and PTENp1 
(PTEN pseudogene 1) was seen to shield PTEN mRNAs 
from miR-21 in oral squamous cell carcinoma (OSCC) 
[210], and from miR-106b and miR-93 in gastric tumours 
[211].
On the other hand, the other group of RNA dark tran-
scripts that are also retrogressed to the genome and 
function as miRNA sponges is that of Short Interspersed 
Nuclear Elements (SINEs) [212]. SINEs include the Alu 
repeated sequences, a family of highly successful genomic 
parasites that have colonised the human genome to the 
extent that over 10% of it (i.e. one million copies) is com-
posed by Alu-derived sequences (see [1] for a recent 
review). Alu repeats incorporated to the human genome 
from a founder element by using the reverse transcriptase 
encoded in LINEs [213, 214], and have subsequently 
undergone a process of sequence degeneration that has 
inactivated their transpositional ability, leaving only a few 
active members in the genome [215]. Genomic Alu ele-
ments include a RNA polymerase III internal promoter at 
the 5′ end of left arm and a short poly-A tail at the 3′ end 
of the right arm [216]. Although most of the members of 
the Alu family are silenced in the human genome, some 
of them are transcribed by RNA polymerase III into free 
Alu RNAs, as concatemers of individual Alu-RNAs by a 
yet unknown mechanism, or by RNA pol-II as mRNA-
embedded Alus [216, 217], this last being a significant 
source of expressed Alu elements since aprox. 30% of 
human genes harbour a copy of an Alu repeat, usually at 
their 5′ or 3′ UTRs [218] (Fig. 3).
Although the functional relationships among Alu ele-
ments and miRNAs are complex and poorly understood, 
mostly due to the dual nature of Alu repeats as free tran-
scripts or mRNA-inserted sequences, it is evident that 
the presence of the highly homologous, Alu repetitive 
sequences in different mRNAs could supply a platform of 
common binding sites for their coordinated targeting by 
miRNAs or to act as miRNA sponges [219]. In this sense, 
it has been reported a subset of 3′UTRs which included 
Alu elements with strong potential target sites for over 50 
different miRNAs [220], and a group of 30 miRNAs that 
showed short-seed homology with highly conserved Alu 
elements at the 3′ UTRs of human mRNAs [221]. Fur-
thermore, miR-15a-3p and miR-302d-3p, were recently 
shown to target RAD1, GTSE1, NR2C1, FKBP9 and 
UBE2I exclusively within Alu elements [222], while miR-
661 caused the downregulation of Mdm2 and Mdm4 by 
interacting with Alu elements in their sequence [223], 
and Di Ruocco et  al. described an Alu RNA that func-
tioned as a miR-566 sponge [224].
Unveiling RNA: RNA regulatory networks 
in the progression of atherosclerosis
Establishing RNA:RNA regulatory networks that 
included mRNAs and miRNAs (and lncRNAs) would 
facilitate our ability to use them for research and thera-
peutic purposes. In this context, we could consider the 
miRNAome as a “safety net” to preserve homeostatic lev-
els of mRNA expression, while lncRNA sponges would 
contribute to maintain regulatory levels of miRNAs. In 
any case, mRNAs, miRNAs and sponging lncRNAs con-
form RNA:RNA regulatory networks that are based on 
their direct physical interaction, which in turn depends 
on the sequence homology.
The first requisite for constructing a regulatory net-
work is to identify the mRNA targets of a specific 
miRNA (or miRNA signature), and the most direct 
way to study these direct interactions is by isolat-
ing hybrid duplexes. A number of methods have been 
designed for this purpose, most of them variations of 
a basic miRNA/target cross-linking and immunopre-
cipitation (CLIP) assay followed by sequencing, such 
as HITS-CLIP [225], miR-CLIP [226], AGO-RIP-Seq 
[227], LIGR-Seq [228], Biotin-Pulldown and RNA-seq 
[229] etc. (see [230] for a recent review on the topic). 
Once miRNA/mRNA pairs have been identified with 
any of the above methods, the interaction is then con-
firmed by a luciferase assay in which the 3′UTR of the 
mRNA to test is cloned downstream a luciferase gene 
and the silencing ability of the miRNA is measured as 
Pol III promoter Pol II promoter




Fig. 3 Role of Alu elements in the regulation of miRNA activity. 
Shown are nuclear Alu elements transcribed from its own RNA pol III 
promoter in the case of being independent transcriptional units (left), 
or from an RNA pol II promoter in the case of being integrated inside 
another gene. In both cases these can behave as miRNA sponges 
by interacting with miRNAs. Some individual Alu elements can 
retroinsert into intergenic regions or inside other transcriptional units 
(taken from [1])
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changes in the light emitted by the construct [231]. 
Nevertheless, all these methods are complex, cumber-
some and time-consuming, and are poorly suited for 
the clinical laboratory, so most of the miRNA work is 
currently performed by using bioinformatic algorithms 
that define miRNA/mRNA interactions (and predicts 
miRNA targets) after measuring sequential, structural 
or thermodynamic features (see [232] for a comprehen-
sive review on the topic). Recent years have seen the 
proliferation of algorithms and web servers designed 
to predict miRNA targets [233], of which a few have 
established themselves as reference tools ([234] and 
see  Table  4). Although it is not the aim of this review 
to make a comparative analysis of these algorithms 
(see [235] for a recent review on this topic), it is widely 
accepted that their predictions are frequently inconsist-
ent, inaccurate and plenty of false positives [236, 237]. 
One answer to this problem has been the development 
of secondary algorithms that perform a more compre-
hensive analysis by combining the outputs of a number 
of primary target predictions (e.g. miRSystem combines 
seven primary algorithms while miRWalk2.0 combines 
12 of them) and allow to control the stringency of the 
search by setting the number of common hits required 
for a prediction to be considered as positive [238, 239], 
but the output of these analysis also are long lists of 
predicted targets. The answer to overcome these prob-
lems has been the development of integrated/enrich-
ment analysis which are well suited to deal with long 
lists of genes, though the results obtained are not so 
solid as those from experimental assays. In the inte-
grated analysis, the list of predicted targets is pruned 
by establishing additional conditions to confirm tar-
gets [240, 241]. Although there are different approaches 
depending on the kind of sequence information avail-
able, a typical experiment would compare the entire list 
of predicted targets for a single miRNA or a miRNA 
signature with a list of Differentially Expressed Genes 
(DEGs) from the same experimental background or 
from an expression repository such as the Gene Expres-
sion Omnibus (GEO) [242], and the entries common to 
both lists would be saved. In a second step, those show-
ing a counter-regulated expression vs. the miRNA/s (i.e. 
inversely correlated expression levels) would integrate 
a restricted list of preferential putative targets (Table 4 
shows different algorithms for integrative analysis). By 
Table 4 Resources for miRNA research
Shown are algorithms and databases for the prediction of miRNA targets, and for the comprehensive and integrated analysis of miRNA/mRNA interactions (see main 
text). This is not an exhaustive list, and the selection only reflects author’s preferences
Algorithm/database Web address Utility References
miRBase www.mirba se.org MiRNA database [250]
miRTarbase mirta rbase .mbc.nctu.edu.tw/php/index .php MiRNA target interaction database [251]
Tarbase www.micro rna.gr/tarba se (& follow link) MiRNA target interaction database [252]
DIANA diana .imis.athen a-iinno vatio n.gr/Diana Tools / MiRNA research tools [253]
doRiNA https ://dorin a.mdc-berli n.de Database of RNA interactions [254]
miRanda https ://omict ools.com/miran da-tool MiRNA target prediction. No longer [255]
mirBridge n.a. MiRNA target prediction [256]
miRDB www.mirbd .org MiRNA target prediction [257]
miRmap https ://mirma p.ezlab .org MiRNA target prediction [258]
miRNAMap mirna map.mbc.nctu.edu.tw MiRNA research tools [259]
PicTar https ://picta r.mdc-berli n.de MiRNA target prediction [260]
PITA http://genie .weizm ann.ac.il/pubs/mir07 /mir07 _predi ction .html MiRNA target prediction [261]
RegRNA regrn a2.mbc.nctu.edu.tw/ RNA-RNA interaction regions [262]
rna22 https ://cm.jeffe rson.edu/rna22 / MiRNA target prediction [263]
RNAhybrid https ://bio.tools /rnahy brid MiRNA target prediction [264]
Targetscan www.targe tscan .org MiRNA target prediction [77]
miRSystem mirsy stem.cgm.ntu.edu.tw/ Comprehensive analysis [238]
miRWalk2.0 zmf.umm.uni-heide lberg .de/apps/zmf/mirwa lk2/ Comprehensive analysis [239]
CORNA omict ools.com/corna s-tool (& follow link) Integrated analysis [265]
MMIA epige nomic s.snu.ac.kr/MMIA/publi c_html/index .html Integrated analysis [266]
miARma-seq http://miarm aseq.idopr otein s.com/ Integrated analysis [241]
DIANA-LncBase carol ina.imis.athen a-innov ation .gr/diana _tools /web/index 
.php?r=lncba sev2%2Find ex
Predicted microRNA targets on lncRNAs [267]
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using a similar approach, Zhang et  al. have recently 
constructed a miRNA:mRNA regulatory network for 
ATH progression in icariin-treated, high-fat fed ApoE-
deficient mice which showed that changes in miRNA 
expression mainly affected the PI3K/Akt, Ras, ErbB and 
VEGF signalling pathways in lesions [243].
The process of delineating RNA regulatory networks 
has been further facilitated by the development of the 
Gene Ontology (GO) enrichment analysis in which 
individual genes from a set of Differentially Expressed 
Genes (DEGs) from a stated condition are classified in 
pre-defined categories (GO-terms) to identify those 
that account for more DEGs (enrichment) [244]. These 
will define gene networks as structural pathways or 
molecular functions specific for that condition. GO 
analysis on ATH-DEGs has showed an enrichment in 
proteins related to nucleic acid function, such as epi-
genetic regulators [245], [liver X] nuclear receptors 
[246], or ribosomal proteins [247], while our own GO 
analysis on a subset of miRNA targets obtained after an 
integrated analysis in ATH also showed an enrichment 
in genes related to the function of nucleic acids (Hueso 
et al., manuscript in preparation).
Lastly, inclusion of lncRNAs in the efforts to delineate 
disease-related regulatory networks greatly increases 
their complexity, not only because this means the inclu-
sion of new players in the game but also because lncR-
NAs are very heterogeneous in function and can act 
at different levels as miRNA sponges, compete with 
miRNAs for shared mRNA targets, or interact with 
the chromatin structure, facts that greatly hinder their 
functional characterization. Furthermore, informa-
tion on the function of individual lncRNAs is scant and 
incomplete for most of them, since only a few hundreds 
of lncRNAs have been yet functionally characterized, 
and for most of them the detailed mechanisms of action 
are still to be determined. Nevertheless, a number of 
groups have reported mutual miRNA:mRNA:lncRNA 
interactions in the context of ATHp ([248, 249] and see 
Table 3).
The dark transcriptome in clinics: future challenges
One of the most striking consequences of the comple-
tion of the human genome has been the conversion of the 
dark transcriptome (encoded by the “junk” DNA) into an 
elaborated catalogue of regulatory RNAs, many of them 
related to the onset and progression of human diseases. 
In this sense, the next challenge is to make profit of this 
ncRNA revolution in the clinical context to explore their 
role as specific biomarkers or as etiopathogenic interme-
diates, but this will require new technical developments 
on the way that sequencing information is generated, 
managed and interpreted.
For many years, the mantra of the sequencing indus-
try has been “faster, longer and cheaper”, and it is likely 
that this will be also the aim for the development of the 
next generation of sequencing machines with the adden-
dum of giving extra importance to accuracy. Sequenc-
ing ncRNAs up to clinical analytical standards is not an 
easy business since it requires an unprecedented degree 
of accuracy and flexibility. Accuracy because detecting 
point mutations in ncRNAs (critical for cancer research) 
cannot be compromised by the technical noise from the 
reagents used for amplifying and generating the sequence 
or from the machine used to detect it [268], and perform-
ing multiplex sequencing in a sample is not the solution 
since this significantly increases the costs associated to 
the process. Flexibility, because ncRNAs are very het-
erogeneous in size and structure, with many events of 
alternative splicing that originate multiple, partially 
homologous, forms that suppose a challenge to recon-
struct long sequences from short reads. Sequencing 
genomic regions rich in clustered repetitive sequences 
(e.g. Alu repeats) pose a similar problem that can only 
be solved by increasing the length of the sequence reads 
without compromising accuracy. Nevertheless, the 
sequencing industry has demonstrated to be innovative 
and dynamic, and although at this time it is difficult to 
ascertain which of the sequencing platforms currently 
in use will rule in the next future, whether different plat-
forms will specialize in specific niches, or if there’s yet to 
come a new and disruptive technology, we can give for 
sure that this problem is being addressed.
The second big challenge to introduce ncRNA expres-
sion profiling in the clinical context has to be with the 
way that the sequencing information generated is man-
aged and used. On the one hand, all this information has 
to be stored in a way that can be easily retrieved, and 
new software has to be developed to extract biological 
or medical “sense” from it. Furthermore, the problem of 
data compatibility and standardization is always behind 
the door. With many different sequencing platforms 
in the market (and other many to come in the future) 
developers should make an effort to share standards and 
avoid proprietary data formats, to encourage data shar-
ing and to provide public, non-commercial and unre-
stricted access to data. Failure on doing this will lead us 
to a nightmare of data islands. On the other hand, data 
interpretation at the whole genome/transcriptome level 
will surely require using artificial intelligence and deep 
learning algorithms for the analysis and to discover new 
biological insights from sequencing data. Genomic data-
sets are too large and complex to be mined by individual 
researchers looking for pairwise correlations, so that the 
need for new and potent analytical tools is clear. Machine 
learning and deep learning, a subdiscipline of machine 
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learning, are powerful tools suited to data-driven sci-
ences that are currently used to automatically explore the 
genome and detect patterns in data that could be used 
to unravel novel properties of noncoding regions and to 
understand how they impact in human health [269, 270]. 
The strong flexibility and high accuracy of deep learning 
methods is supported by the successive introduction of a 
variety of deep architectures that are superior over other 
existing methods. In this sense, Splice AI, a deep neural 
network, has been used to predict splice junctions from 
a pre-mRNA transcript, as well as noncoding variants 
with the ability to cause cryptic splicing events [271]. It 
is likely that many other similar algorithms will be devel-
oped to assist the analysis of whole transcriptomes/
genomes.
Conclusions
We are on the verge of a new revolution in the way we 
see disease and the normal, non-diseased state. For 
many years, diseases have been linked to mutations in 
the genomic DNA or to alterations in the expression of 
coding mRNAs. We now know that this “coding world” 
is just the tip of the gene expression iceberg. It is not 
only that there are more non-coding RNAs than coding 
ones, but that all these RNAs interact among them (and 
with chromatin), to create complex regulatory miRNA/
lncRNA/mRNA networks whose unbalance underlies the 
basis of complex diseases. Constructing accurate models 
of disease, a requisite for developing new and personal-
ized treatments, will require new developments to gener-
ate accurate sequencing information as well as to make 
this information manageable and available to all ranks 
involved in alleviating the burden associated to human 
diseases.
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